MENU
+Compare
RLYB
Stock ticker: NASDAQ
AS OF
May 13 closing price
Price
$0.30
Change
-$0.00 (-0.00%)
Capitalization
12.4M

RLYB Rallybio Corp Forecast, Technical & Fundamental Analysis

Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders... Show more

RLYB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for RLYB with price predictions
May 12, 2025

RLYB's Stochastic Oscillator remains in oversold zone for 2 days

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RLYB's RSI Indicator exited the oversold zone, of 21 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on May 12, 2025. You may want to consider a long position or call options on RLYB as a result. In of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for RLYB just turned positive on April 23, 2025. Looking at past instances where RLYB's MACD turned positive, the stock continued to rise in of 37 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RLYB advanced for three days, in of 212 cases, the price rose further within the following month. The odds of a continued upward trend are .

RLYB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RLYB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for RLYB entered a downward trend on April 17, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.229) is normal, around the industry mean (14.807). P/E Ratio (0.000) is within average values for comparable stocks, (65.734). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.164). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (15.649) is also within normal values, averaging (254.778).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. RLYB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLYB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
RLYB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

RLYB is expected to report earnings to rise 20.62% to -25 cents per share on August 06

Rallybio Corp RLYB Stock Earnings Reports
Q2'25
Est.
$-0.25
Q1'25
Beat
by $0.07
Q4'24
Beat
by $0.55
Q3'24
Beat
by $0.09
Q2'24
Missed
by $0.30
The last earnings report on May 08 showed earnings per share of -20 cents, beating the estimate of -28 cents. With 48.44K shares outstanding, the current market capitalization sits at 12.40M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
234 Church Street
Phone
+1 203 859-3820
Employees
43
Web
https://www.rallybio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA334.0715.69
+4.93%
Tesla
BTC.X104169.8100001356.851600
+1.32%
Bitcoin cryptocurrency
GME28.390.34
+1.21%
GameStop Corp
AAPL212.932.14
+1.02%
Apple
SPY586.843.85
+0.66%
SPDR® S&P 500® ETF

RLYB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RLYB has been loosely correlated with ATXS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if RLYB jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLYB
1D Price
Change %
RLYB100%
+2.70%
ATXS - RLYB
42%
Loosely correlated
+3.31%
PRME - RLYB
40%
Loosely correlated
+3.08%
SLNO - RLYB
38%
Loosely correlated
-0.10%
GBIO - RLYB
38%
Loosely correlated
+8.44%
IMCR - RLYB
35%
Loosely correlated
+4.01%
More